Developing a Platform for Large-Scale
Lentiviral Manufacture
Presenter:
Yiyu Dong, PhDAssociate Director of Viral Vector Process
Technology Development (VVPTD),
WuXi Advanced Therapies
Yiyu Dong has more than 16 years of experience with cell line and bioprocess development. At WuXi Advanced Therapies, he specializes in leading and developing high-producing clonal cell lines and robust and scalable AAV and lentiviral suspension platforms. His main goal is to develop robust and cost-effective viral vector production processes for clinical and commercial manufacturing.
Prior to WuXi Advanced Therapies, Yiyu Dong held positions in industry and academia with a focus on discovering and developing novel platforms and targets for treating human diseases. He performed translational medicine research at Memorial Sloan Kettering Cancer Center and published 29 peer-reviewed papers. Yiyu Dong holds a PhD from a joint program between Peking University and Yale University.
